Microvascular Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Microvascular Therapeutics is a clinical-stage biotech company leveraging a proprietary microbubble and nanobubble platform to transform ultrasound from a diagnostic imaging tool into a therapeutic modality. Its diversified pipeline targets significant unmet needs in cardiology, oncology, neurology, and ophthalmology, with its lead program, MVT-100, having completed Phase II trials. The company is led by a founder with a proven track record in ultrasound contrast agent development and commercialization, and it is advancing its programs through strategic partnerships and non-dilutive grant funding.

CardiologyOncologyNeurologyOphthalmology

Technology Platform

Proprietary microbubble and phase-shift nanobubble platforms for ultrasound contrast imaging, targeted drug delivery, and image-guided tissue ablation.

Opportunities

MVT's platform technology enables the transformation of ubiquitous ultrasound machines into therapeutic devices, opening multi-billion dollar markets in non-invasive tumor ablation, targeted drug delivery for Alzheimer's and cancer, and improved diagnostic imaging.

The low cost and wide availability of ultrasound could lead to rapid global adoption and address significant unmet medical needs with more precise and less toxic treatments.

Risk Factors

The company faces high clinical development risk, as all therapeutic programs are in early stages.

As a pre-revenue private company, it is dependent on raising capital and grant funding to advance its pipeline, creating significant financing risk.

It must also overcome commercial competition from established ultrasound contrast agents and pioneer new clinical paradigms for its theranostic applications.

Competitive Landscape

In ultrasound contrast, MVT competes with large commercial players like Lantheus (Definity) and GE Healthcare (Optison). In theranostics, competition is broader and includes focused ultrasound companies (e.g., Insightec), drug developers targeting similar indications, and other nanomedicine platforms. MVT's differentiation lies in its specific bubble formulations, neutral shell chemistry, and a leadership team with unparalleled experience in commercializing ultrasound contrast agents.

More companies in Diagnostics & Precision Medicine →More companies in United States →